GlassScriptPhysician profile
Kyle M Tipton
NPI 1245253061
$5,912.51
in general payments reported to CMS, 2019-2025
44 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $380 · 2021: $756 · 2022: $996 · 2023: $1,044 · 2024: $1,375 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $839.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $677.43 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $602.56 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $457.14 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $363.85 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $318.41 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $296.08 | 2019-2025 | |
| Amarin Pharma, INC. | $239.68 | 2019-2022 | |
| Abbott Laboratories | $231.32 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $185.89 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $153.88 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $113.33 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $107.02 | 2024-2025 | Rexulti |
| Eisai INC. | $105.34 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.13 | 2023-2025 | Jardiance |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Tipton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.